BRAF and tarsal-carpal coalition syndrome: Overall, these findings suggest that detection and quantification of the BRAF mutation in canine TCC patients, especially through non-invasive techniques, could be very useful in the clinical setting, not only as a biomarker for diagnosis, but also for monitoring disease progression and treatment response.